TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12594876

Group type: EXPERIMENTAL
Intervention: Ventilator weaning protocol (WP)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Ventilator weaning protocol (WP) + chlorhexidine 0.12% oral rinse administered twice daily
Number of subjects: 95
Study: 9743218

Group type: EXPERIMENTAL
Intervention: Fc gamma receptor II (Fc gammaRII) and Fc gamma receptor III (Fc gammaRIII) expression on monocytes stained with specific monoclonal antibodies (IV.3 and 3G8)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Impaired clearance function
Number of subjects: 0
Study: 7848929

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA) with 0.1% bupivacaine, 0.01% morphine sulfate
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (IV-PCA)
Number of subjects: 462
Study: 3240766

Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30903118

Group type: EXPERIMENTAL
Intervention: Fluoride sealants
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Non-fluoride sealants
Number of subjects: 400

Group type: COMPARATOR
Intervention: Sealant placement (both fluoride and non-fluoride)
Number of subjects: 400
Study: 28477306

Group type: EXPERIMENTAL
Intervention: Migraine patients
Number of subjects: 34
Study: 25452446

Group type: EXPERIMENTAL
Intervention: Apricoxib 400 mg once per day with docetaxel 75 mg/m2 or pemetrexed 500 mg/m2 once every 21 days
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo with docetaxel 75 mg/m2 or pemetrexed 500 mg/m2 once every 21 days
Number of subjects: 72
Study: 23186975

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily (OD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg OD
Number of subjects: 0

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 0
Study: 22162646

Group type: EXPERIMENTAL
Intervention: Initial six-month lifestyle intervention for obesity
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Follow-up assessment 3.5 years later
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Successful participants (maintained losses of 5% or greater)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Self-monitoring behaviors
Number of subjects: 110
Study: 17875305

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg QD
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg QD
Number of subjects: 122
Study: 17262147

Group type: EXPERIMENTAL
Intervention: Retrofilling with MTA after Er;Cr:YSGG laser irradiation (2.78 microm, 4 W, 20 Hz, 70.8 J/cm(2))
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Retrofilling with cyanoacrylate after Er;Cr:YSGG laser irradiation
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Retrofilling with MTA without laser irradiation
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Retrofilling with cyanoacrylate without laser irradiation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Positive control (not specified)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Negative control (not specified)
Number of subjects: 22
Study: 12657338

Group type: EXPERIMENTAL
Intervention: Environmental and policy interventions for physical activity
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Environmental and policy interventions for fat intake
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Environmental and policy interventions
Number of subjects: 24
Study: 11094868

Group type: EXPERIMENTAL
Intervention: recombinant human IL-10 (rHuIL-10) at doses of 5, 10, or 20 micrograms/kg, administered subcutaneously, once daily for 28 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study: 9365526

Group type: EXPERIMENTAL
Intervention: recombinant human granulocyte-colony stimulating factor (rhG-CSF) administered after the first or second chemotherapy cycle
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: high-dose chemotherapy and rhG-CSF
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 12
Study: 1554036

Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg daily
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Haloperidol 10 mg daily
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Haloperidol 20 mg daily
Number of subjects: 69

Group type: COMPARATOR
Intervention: Plasma haloperidol levels above 12 ng/ml
Number of subjects: 69
Study: 2867575

Group type: EXPERIMENTAL
Intervention: Real ECT
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham ECT
Number of subjects: 70
Study: 30992024

Group type: EXPERIMENTAL
Intervention: Preparing for dialysis
Number of subjects: 16

Group type: COMPARATOR
Intervention: Preparing for conservative care
Number of subjects: 16
Study: 30072213

Group type: EXPERIMENTAL
Intervention: BKV or CMV viral loads over 10,000 copies·mL‐1
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: BKV-CMV combined reactivation
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: EBV reactivation
Number of subjects: 540
Study: 26278005

Group type: EXPERIMENTAL
Intervention: Extended morning fasting
Number of subjects: 24
Study: 25621158

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 12
Study: 22298867

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 1500 mL of an isotonic solution per day for 6 days
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Home oral hydration therapy of 1500 mL/d (subgroup A1)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Home oral hydration therapy of 2500 mL/d (subgroup A2)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Normal pregnancies without oligohydramnios (control group B)
Number of subjects: 137
Study: 20022201

Group type: EXPERIMENTAL
Intervention: Pedometer-based telephone intervention
Number of subjects: 215

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 215
Study: 17908193

Group type: EXPERIMENTAL
Intervention: Cotton pajamas
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polyester pajamas
Number of subjects: 0
Study: 15064300

Group type: EXPERIMENTAL
Intervention: Progressive exercise in normoxia (N)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Progressive exercise in hypoxia (H)
Number of subjects: 9
Study: 11588406

Group type: EXPERIMENTAL
Intervention: Olmesartan (20 mg)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Losartan (50 mg)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Valsartan (80 mg)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Irbesartan (150 mg)
Number of subjects: 588
Study: 9718376

Group type: EXPERIMENTAL
Intervention: Subcutaneous epoetin
Number of subjects: 208

Group type: COMPARATOR
Intervention: Intravenous epoetin
Number of subjects: 208
Study: 7639807

Group type: EXPERIMENTAL
Intervention: High-dose omega 3 fatty acids (130 mg/kg/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Corn oil (9 capsules/day)
Number of subjects: 66
Study: 2619780

Group type: EXPERIMENTAL
Intervention: Euphylong-pellets (formulation E)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference formulation (twice-daily dosage)
Number of subjects: 18
Study: 849537

Group type: EXPERIMENTAL
Intervention: Ocusert Pilocarpine (P20)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ocusert Pilocarpine (P40)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aqueous pilocarpine drops
Number of subjects: 0
Study: 31809326

Group type: EXPERIMENTAL
Intervention: Ipilimumab followed by nab-paclitaxel and bevacizumab (AB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nab-paclitaxel and bevacizumab (AB) followed by ipilimumab
Number of subjects: 0
Study: 30768493

Group type: EXPERIMENTAL
Intervention: Otilonium bromide and simethicone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 120
Study: 28290764

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cardiovascular exercise
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Postural exercise
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 24939678

Group type: EXPERIMENTAL
Intervention: CDS-guided temporal artery biopsy (TAB)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard temporal artery biopsy (TAB)
Number of subjects: 112
Study: 23232255

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5%
Number of subjects: 88

Group type: COMPARATOR
Intervention: Prednisolone acetate 1.0%
Number of subjects: 88
Study: 21310829

Group type: EXPERIMENTAL
Intervention: Protein Hydrolysate Formula (PHF) for 3 months
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Protein Hydrolysate Formula (PHF) for 1 month starting at 3.5 months
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Protein Hydrolysate Formula (PHF) for 7 months
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cow Milk-Based Formula (CMF)
Number of subjects: 6
Study: 19342148

Group type: EXPERIMENTAL
Intervention: ART restorations with cavity disinfection
Number of subjects: 90

Group type: COMPARATOR
Intervention: ART restorations without cavity disinfection
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All ART restorations
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Single-surface ART restorations
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Multiple-surface ART restorations
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All ART restorations by gender
Number of subjects: 90
Study: 15925816

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg orally once a day) and Anastrozole (1 mg orally once a day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Gefitinib (250 mg orally once a day)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Gefitinib and Anastrozole
Number of subjects: 56

Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study: 12061685

Group type: EXPERIMENTAL
Intervention: Helical CT cholangiography (CT/+ group, n = 13)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No helical CT cholangiography (CT/- group, n = 15)
Number of subjects: 53
Study: 10404575

Group type: EXPERIMENTAL
Intervention: Multifidus muscle vibration (70 Hz, 0.5 mm amplitude for approximately 5 seconds)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (only heard the vibrator noise)
Number of subjects: 25
Study: 9002913

Group type: EXPERIMENTAL
Intervention: Anthropometric measures (body and knee heights)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Serum levels of DHEAS and osteocalcin measured every three months
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Physical measures (height and skeletal maturation)
Number of subjects: 46
Study: 2340834

Group type: EXPERIMENTAL
Intervention: L-dopa/bromocriptine
Number of subjects: 31

Group type: COMPARATOR
Intervention: L-dopa alone
Number of subjects: 31
Study: 6988462

Group type: EXPERIMENTAL
Intervention: Tru-Cut sheathed needle
Number of subjects: 77

Group type: COMPARATOR
Intervention: Menghini suction biopsy needle
Number of subjects: 77
Study: 31746443

Group type: EXPERIMENTAL
Intervention: MIPO
Number of subjects: 163

Group type: COMPARATOR
Intervention: IMN
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 163
Study: 31070845

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment
Number of subjects: 13

Group type: COMPARATOR
Intervention: Desoximetasone ointment
Number of subjects: 13
Study: 27727138

Group type: EXPERIMENTAL
Intervention: Interactive online curriculum with weekly reading assignments (GROUP 1)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No access to the online curriculum (GROUP 2)
Number of subjects: 53
Study: 25040299

Group type: EXPERIMENTAL
Intervention: 0.07% cetylpyridinium chloride (CPC) mouth rinse
Number of subjects: 62

Group type: COMPARATOR
Intervention: Vehicle control (VC) mouth rinse
Number of subjects: 62
Study: 23589230

Group type: COMPARATOR
Intervention: Squatting alone (S)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Squatting + vibration (SV)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Squatting + external load (SE)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Squatting + external load + vibration (SEV)
Number of subjects: 6
Study: 21320366

Group type: EXPERIMENTAL
Intervention: MUFA diet (n=39)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: LF diet (n=43)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control diet (n=24)
Number of subjects: 106
Study: 19944363

Group type: EXPERIMENTAL
Intervention: Moderate sodium restriction (120mmol to 2.8g/day) plus oral furosemide (125 to 250mg bid)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Low-sodium diet (80mmol to 1.8g/day) plus oral furosemide (125 to 250mg bid)
Number of subjects: 173
Study: 17417709

Group type: EXPERIMENTAL
Intervention: Bipolar cutting scissors technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard scalpel blade technique
Number of subjects: 60
Study: 15470333

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 21
Study: 11432485

Group type: EXPERIMENTAL
Intervention: Meropenem (50 mg/kg/dose, maximum 1 g, every 8 hours)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Piperacillin (200 mg/kg/dose, every 6 hours) plus Amikacin (15 mg/kg daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gram-positive culture
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gram-negative or mixed cultures
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Solid tumor group
Number of subjects: 90
Study: 9712234

Group type: EXPERIMENTAL
Intervention: IgG serology (Orion Diagnostica Pyloriset New EIA‐G)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Capsule 14C urea breath test (UBT)
Number of subjects: 794

Group type: COMPARATOR
Intervention: Rapid urease test (RUT)
Number of subjects: 794

Group type: COMPARATOR
Intervention: Culture
Number of subjects: 794

Group type: COMPARATOR
Intervention: Non-capsule UBT
Number of subjects: 794

Group type: COMPARATOR
Intervention: Capsule UBT
Number of subjects: 794
Study: 8308505

Group type: EXPERIMENTAL
Intervention: Fluticasone aqueous nasal spray 100 micrograms twice daily
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Fluticasone aqueous nasal spray 200 micrograms once daily
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Beclomethasone aqueous nasal spray 168 micrograms twice daily
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study: 2658700

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide 200 micrograms
Number of subjects: 7

Group type: COMPARATOR
Intervention: Inhaled propranolol
Number of subjects: 7

Group type: COMPARATOR
Intervention: Methacholine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 7
Study: 5272349

Group type: EXPERIMENTAL
Intervention: Cendehill rubella virus vaccine
Number of subjects: 16000
Study: 31669047

Group type: EXPERIMENTAL
Intervention: e‐Counseling
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control
Number of subjects: 264
Study: 29637645

Group type: EXPERIMENTAL
Intervention: Reach-to-Recovery (RTR) + PA
Number of subjects: 76

Group type: COMPARATOR
Intervention: RTR Control
Number of subjects: 76
Study: 28364870

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (o-CEE, 0.45mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal 17β estradiol (t-E2, 50μg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo pills and patches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatment groups (o-CEE, t-E2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three years after discontinuation of study treatments
Number of subjects: 0
Study: 26176878

Group type: EXPERIMENTAL
Intervention: Lidocaine 5% patches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 0
Study: 23615094

Group type: EXPERIMENTAL
Intervention: Gamma Knife Radiosurgery (GKRS)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Conservative Management (CM)
Number of subjects: 237
Study: 21306826

Group type: EXPERIMENTAL
Intervention: Psychological distress (depression and stress)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Symptoms of depression and stress
Number of subjects: 231

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 231
Study: 19544653

Group type: EXPERIMENTAL
Intervention: Basic therapy plus ozone therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Basic therapy
Number of subjects: 42
Study: 17205825

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg once per day after breakfast for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Xiaoyao Decoction (XD) and Wendan Decoction (WD) one dose a day before supper for 8 weeks
Number of subjects: 0
Study: 12885809

Group type: EXPERIMENTAL
Intervention: Number of lymph nodes analyzed from surgical specimens
Number of subjects: 3411

Group type: COMPARATOR
Intervention: No lymph node involvement
Number of subjects: 3411
Study: 10533862

Group type: EXPERIMENTAL
Intervention: Cuprophan membranes
Number of subjects: 180

Group type: COMPARATOR
Intervention: Polymethyl-methacrylate membranes
Number of subjects: 180
Study: 8739053

Group type: EXPERIMENTAL
Intervention: Coculture with autologous cryopreserved endometrial cells
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no coculture)
Number of subjects: 21
Study: 1718366

Group type: COMPARATOR
Intervention: 2 mg Cu/d
Number of subjects: 21

Group type: COMPARATOR
Intervention: 3 mg Cu/d
Number of subjects: 21
Study: 6173204

Group type: EXPERIMENTAL
Intervention: Electrical constant current stimuli (20 msec, 2‐8 mA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical force controlled stimuli (20 msec, 0.8‐3.2 N)
Number of subjects: 0
Study: 31329216

Group type: EXPERIMENTAL
Intervention: AZD0530 (100 mg or 125 mg daily)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: AZD0530
Number of subjects: 159
Study: 27106926

Group type: EXPERIMENTAL
Intervention: Knee joint distraction
Number of subjects: 69

Group type: COMPARATOR
Intervention: High tibial osteotomy (HTO)
Number of subjects: 69
Study: 25724985

Group type: EXPERIMENTAL
Intervention: MVA-B vaccine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MVA-B/disulfiram
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 24001464

Group type: EXPERIMENTAL
Intervention: Shared care cardiac rehabilitation (SC-CR)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Hospital-based cardiac rehabilitation (H-CR)
Number of subjects: 208
Study: 21251283

Group type: EXPERIMENTAL
Intervention: Low-fat diet (LF)
Number of subjects: 17

Group type: COMPARATOR
Intervention: High-fat diet (HF)
Number of subjects: 17
Study: 19476398

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 0
Study: 17463301

Group type: EXPERIMENTAL
Intervention: Severe Intermittent Hypoxia (SIH) - 12% O2 for 1 h/day, 5 days/week for 8 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moderate Intermittent Hypoxia (MIH) - 15% O2 for 1 h/day, 5 days/week for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 20
Study: 15063421

Group type: EXPERIMENTAL
Intervention: Sildenafil (25 to 100 mg thrice daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 11568190

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) of the lumbar spine in 1989
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Repeat magnetic resonance imaging scans
Number of subjects: 50

Group type: COMPARATOR
Intervention: Original MRI scans from 1989
Number of subjects: 50
Study: 11055475

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (30-60 mg)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Enalapril (5-10 mg)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS and Enalapril
Number of subjects: 186
Study: 9070958

Group type: EXPERIMENTAL
Intervention: Aspirin (50 mg) plus dipyridamole (150 mg/day)
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Aspirin (50 mg) plus ticlopidine (200 mg/day)
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Antiplatelet agents (combined treatment)
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Nontreatment group
Number of subjects: 1083
Study: 8444627

Group type: EXPERIMENTAL
Intervention: Initial aerobic capacity, depression, anxiety; changes in depression and social activity at 3 months
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Initial anxiety and physical activity, change in depression, support of friends for exercise, exercise behavior at prior assessment at 9 months
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Initial aerobic capacity, change in pain, exercise behavior at the two prior assessments at 18 or more months
Number of subjects: 120
Study: 3723262

Group type: EXPERIMENTAL
Intervention: Rice powder ORS (30 g/L of rice powder)
Number of subjects: 50

Group type: COMPARATOR
Intervention: WHO recommended glucose ORS (20 g/L of glucose)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rice powder ORS
Number of subjects: 50

Group type: COMPARATOR
Intervention: WHO recommended glucose ORS
Number of subjects: 50
Study: 29856344

Group type: EXPERIMENTAL
Intervention: Inactivated varicella zoster vaccine (vaccine consistency lot group)
Number of subjects: 1230

Group type: EXPERIMENTAL
Intervention: Inactivated varicella zoster vaccine (high-antigen lot group)
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1230

Group type: EXPERIMENTAL
Intervention: Combined vaccine groups
Number of subjects: 1230

Group type: EXPERIMENTAL
Intervention: Inactivated varicella zoster vaccine
Number of subjects: 1230
Study: 27632360

Group type: EXPERIMENTAL
Intervention: Telephone-Based Health Coaching (TBHC)
Number of subjects: 6208
Study: 24389524

Group type: EXPERIMENTAL
Intervention: High-light physical activity (HLPA): 2.1-2.9 METs
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Low-light physical activity (LLPA): 1.5-2.0 METs
Number of subjects: 641

Group type: COMPARATOR
Intervention: Moderate to vigorous physical activity (MVPA): ≥3.0 METs
Number of subjects: 641